Who are Placebo to Palonosetron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Zofran inj.+Zofran tab., Ramosetron, Aprepitant, Dexamethasone, Ondansetron (ODT), ondansetron and dyclonine hydrochloride, fosnetupitant/ palonosetron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-palonosetron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to Palonosetron — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Palonosetron (Placebo to Palonosetron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology.

phase 3 5-HT3 receptor antagonist 5-HT3 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Palonosetron (Placebo to Palonosetron) — Helsinn Healthcare SA. Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to Palonosetron TARGET	Placebo to Palonosetron	Helsinn Healthcare SA	phase 3	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Zofran inj.+Zofran tab.	Zofran inj.+Zofran tab.	LG Life Sciences	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Ramosetron, Aprepitant, Dexamethasone	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Ondansetron (ODT)	Ondansetron (ODT)	MonoSol Rx	marketed	5-HT3 receptor antagonist	5-HT3 receptor
ondansetron and dyclonine hydrochloride	ondansetron and dyclonine hydrochloride	Peking Union Medical College Hospital	marketed	5-HT3 receptor antagonist with local anesthetic	5-HT3 receptor; local anesthetic (sodium channel blockade)
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

Helsinn Healthcare SA · 4 drugs in this class
LG Life Sciences · 3 drugs in this class
University of Malaya · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Hamad Medical Corporation · 1 drug in this class
Eye & ENT Hospital of Fudan University · 1 drug in this class
Instituto Mexicano del Seguro Social · 1 drug in this class
Chongqing University Cancer Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
MonoSol Rx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Palonosetron — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-palonosetron. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab